Does dapagliflozin reduce the incidence of reported episodes of AF/AFL adverse events in high-risk patients with type 2 diabetes mellitus?
Dapagliflozin reduces the incidence of atrial fibrillation and atrial flutter adverse events in high-risk patients with type 2 diabetes mellitus.
Dapagliflozin decreased the incidence of reported episodes of AF/AFL adverse events in high-risk patients with type 2 diabetes mellitus. This effect was consistent regardless of the patient's previous history of AF, atherosclerotic cardiovascular disease, or HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01730534.
Zelniker et al. (Mon,) studied this question.